GlassScriptPhysician profile
Christina Friedly
NPI 1366920373
$3,411.81
in general payments reported to CMS, 2019-2025
32 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.15 · 2022: $322 · 2023: $887 · 2024: $1,059 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,037.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.35 | 2022-2025 | |
| Pfizer INC. | $375.18 | 2022-2025 | |
| Astellas Pharma US INC | $278.89 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $209.04 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.05 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $174.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $154.45 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $151.27 | 2022-2025 | Wegovy, Ozempic |
| Axsome Therapeutics, INC. | $145.07 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $137.02 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.33 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.83 | 2023-2025 | Xifaxan |
| Antares Pharma, INC. | $93.69 | 2024-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $74.99 | 2022-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $65.77 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $51.64 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $50.94 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $43.35 | 2021-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $40.88 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $39.37 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $38.02 | 2023-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $37.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $35.88 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $33.97 | 2023-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Dynavax Technologies Corporation | $32.08 | 2023-2024 | Heplisav-B |
| Tactile Systems Technology INC | $27.96 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Dexcom, INC. | $24.82 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $21.96 | 2025 | |
| Sanofi Pasteur INC. | $20.74 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $20.09 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $15.17 | 2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Friedly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.